Ritholtz Wealth Management Takes Position in Oramed Pharmaceuticals Inc. $ORMP

Ritholtz Wealth Management acquired a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 155,479 shares of the biotechnology company’s stock, valued at approximately $529,000. Ritholtz Wealth Management owned 0.38% of Oramed Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Redwood Family Wealth LLC bought a new stake in Oramed Pharmaceuticals in the 4th quarter worth approximately $66,000. SB Capital Management Inc purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth $5,415,000. XTX Topco Ltd grew its holdings in shares of Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 14,297 shares during the period. Quadrature Capital Ltd purchased a new stake in Oramed Pharmaceuticals during the fourth quarter valued at $119,000. Finally, Squarepoint Ops LLC lifted its holdings in Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 28,406 shares during the period. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $4.81 on Wednesday. Oramed Pharmaceuticals Inc. has a one year low of $1.98 and a one year high of $5.19. The business has a fifty day moving average price of $4.07 and a 200-day moving average price of $3.60. The firm has a market capitalization of $196.87 million, a price-to-earnings ratio of 1.86 and a beta of 1.26.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Oramed Pharmaceuticals currently has an average rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.